Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Trial Profile

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2019

At a glance

  • Drugs Berzosertib (Primary) ; Carboplatin; Cisplatin; Etoposide; Gemcitabine; Irinotecan
  • Indications Advanced breast cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors EMD Serono Research & Development Institute; Merck KGaA; Vertex Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2019 Status changed from recruiting to active, no longer recruiting.
    • 18 Feb 2019 Planned number of patients changed from 194 to 198.
    • 08 Oct 2018 According to a Merck KGaA media release, data from this study will be presented at the European Society for Medical Oncology Annual Meeting (ESMO) 2018 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top